Cargando…

Editorial: Recent advancement of the cardio-renal protective effects of SGLT2 inhibitors in people with and without diabetes

Detalles Bibliográficos
Autores principales:	Kuriyama, Satoru, Nakayama, Masaaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641902/ https://www.ncbi.nlm.nih.gov/pubmed/37964889 http://dx.doi.org/10.3389/fmed.2023.1293372

Ejemplares similares

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
por: Capuano, Annalisa, et al.
Publicado: (2022)

Editorial: Recent advances on omics and biomarkers research in renal transplantation
por: Ding, Xiaoming, et al.
Publicado: (2023)

Possible renoprotective mechanisms of SGLT2 inhibitors
por: Nishiyama, Akira, et al.
Publicado: (2023)

Editorial: Cardio-oncology: mechanisms and therapeutics
por: Ma, Yan, et al.
Publicado: (2023)

Editorial: Recent advances in refractive surgery
por: Kamiya, Kazutaka, et al.
Publicado: (2023)

Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Li, Ning, et al.
Publicado: (2021)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
por: Li, Lu-Feng, et al.
Publicado: (2021)

Editorial: Respiratory Virus Infection: Recent Advances
por: Peltola, Ville, et al.
Publicado: (2020)

Editorial: Recent updates in advanced gastrointestinal endoscopy
por: Perisetti, Abhilash, et al.
Publicado: (2023)

Editorial: Cardio-Oncology: From Bench to Bedside
por: Abe, Jun-ichi, et al.
Publicado: (2019)

Editorial: Case reports in cardio-oncology: 2022
por: Ewer, Michael S., et al.
Publicado: (2023)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review
por: Kalluri, Sahithi Reddy, et al.
Publicado: (2021)

Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
por: Wang, Anzhu, et al.
Publicado: (2022)

Editorial: Recent advances and new biomarkers in ulcerative colitis
por: Velikova, Tsvetelina, et al.
Publicado: (2023)

Editorial: CardioNeurology: Basic, translational and clinical research
por: Roever, Leonardo, et al.
Publicado: (2023)

In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
por: Cesaro, Arturo, et al.
Publicado: (2022)

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022)

Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy
por: Dong, Yaping, et al.
Publicado: (2023)

Editorial: Recent Advances in Endothelial Progenitor Cells Toward Their Use in Clinical Translation
por: Medina, Reinhold J., et al.
Publicado: (2020)

Editorial: Recent advances in keratinocyte carcinomas: From molecular mechanisms to clinical perspectives
por: Caruntu, Constantin, et al.
Publicado: (2022)

Is There a Diabetes–Kidney–Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors
por: Bao, Liwen, et al.
Publicado: (2021)

Editorial: Chronic inflammation, oxidative stress and lipoprotein metabolism in cardio-pulmonary continuum
por: Sorokin, Alexander V., et al.
Publicado: (2022)

Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
por: Margonato, Davide, et al.
Publicado: (2020)

Molecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
por: Hou, Yi-Chou, et al.
Publicado: (2020)

An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
por: Salvatore, Teresa, et al.
Publicado: (2022)

Editorial to the IJMS Special Issue on Sglt2 Inhibitors Vol. 1
por: Lymperopoulos, Anastasios
Publicado: (2023)

Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes
por: Gronda, Edoardo G., et al.
Publicado: (2022)

Editorial: Emerging Challenges of Cardiovascular and Metabolic Dysfunctions in Cardio-Oncology: From Bench to Bedside
por: Nebigil, Canan G., et al.
Publicado: (2020)

Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors
por: Scholtes, Rosalie A., et al.
Publicado: (2021)

SGLT2 inhibitors and renal complications in type 1 diabetes
por: Petrie, John R
Publicado: (2020)

Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
por: Ren, Qian, et al.
Publicado: (2022)

From “Heart and Reins” to Clinical Syndromes: Origin and Evolution of Cardio-Renal Disease
por: Salam, Amar M., et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Editorial: Covid-19 Mechanisms on Cardio-Vascular Dysfunction: From Membrane Receptors to Immune Response
por: Wanschel, Amarylis C. B. A., et al.
Publicado: (2021)

Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2021)

COP27 Climate Change Conference Editorial, TAVI, SGLT2 inhibitors…
por: Erol, Çetin
Publicado: (2022)

Editorial: Cardio-Protection and Heart Repair: New Drugs, Targets and Approaches
por: Zagidullin, Naufal, et al.
Publicado: (2021)

Recent Updates and Advances in the Use of Glycated Albumin for the Diagnosis and Monitoring of Diabetes and Renal, Cerebro- and Cardio-Metabolic Diseases
por: Giglio, Rosaria Vincenza, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s5ob8tqevabjf2fbgk3qkrn3p4